Sarepta shares slammed on report gene therapy Duchenne MD patient was hospitalized, but the company says it is 'erroneous'
Sarepta has some explaining to do.
The biotech’s shares $SRPT nose dived 13% on Thursday after a report surfaced that one of the children in its gene therapy study was hospitalized with rhabdomyolysis in February, which hit the FDA’s adverse event roster. Its shares then plunged 13% before trading was halted.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,800+ biopharma pros reading Endpoints daily — and it's free.
UPDATED: In a stunning turnaround, Biogen says that aducanumab does work for Alzheimer's — but data mining incites controversy and questions
Biogen has confounded the biotech world one more time.
In a stunning about-face, the company and its partners at Eisai say that a new analysis of a larger dataset on aducanumab has restored its faith in the drug as a game-changer for Alzheimer’s and, after talking it over with the FDA, they’ll now be filing for an approval of a drug that had been given up for dead.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,800+ biopharma pros reading Endpoints daily — and it's free.
UPDATED: Failed PhIII fevipiprant trials pour more cold water on Novartis' blockbuster R&D engine — and briefly spread the chill to a high-profile biotech
Back in July, during an investor call where Novartis execs ran through an upbeat assessment of their Q2 performance, CEO Vas Narasimhan and development chief John Tsai were pressed to predict which of the two looming Phase III readouts — involving cardio drug Entresto and asthma therapy fevipiprant, respectively — had a higher likelihood of success. Tsai gave the PARAGON-HF study with Entresto minimally better odds, but Narasimhan emphasized that their strategy of giving fevipiprant to more severe patients gave them confidence.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,800+ biopharma pros reading Endpoints daily — and it's free.
David Liu unveils newest advancement in CRISPR tech: Prime editing
The researcher behind base-editing is out with what some scientists are hailing as the biggest advancement in CRISPR technology since that 2016 breakthrough: “prime editing.” The new molecular gadget is capable of erasing any base pair and stenciling in another and cutting or adding long segments of DNA without breaking both strands of the helix.
David Liu, base editing pioneer and founder of Beam Therapeutics, published the findings in Nature alongside Andrew Anzalone. They estimated that the breakthrough “in principle” puts 89% of human diseases in purview — although experts cautioned that human therapies were a long way off.
Frazier Healthcare Partners' dermatology upstart attracts a marquee syndicate, $94M+ for 'in-between' topical drug
For the past three years Frazier Healthcare Partners’ Bhaskar Chaudhuri has been carefully and quietly grooming Arcutis Therapeutics, a new dermatology play he co-founded to deliver topical formulations of well-known drugs. Now that the biotech is poised to enter Phase III, he’s being joined by a marquee syndicate for its $94.5 million Series C.
HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs jumped on board, joining Bain Capital Life Sciences, OrbiMed and RA Capital Management in backing Arcutis’ lead topical cream for plaque psoriasis.
A new company enters the Tecfidera fight, offering to kill two birds
The remedy for the most common side effect for one of the most common multiple sclerosis drugs is simple: aspirin.
Taking aspirin with Biogen’s Tecfidera will reduce the flush, a sometimes painful form of red skin irritation, many patients experiences. The problem is that the aspirin has to be taken at least 30 minutes before Tecfidera, turning a simple twice-a-day, one-dose oral drug into a staggered two-drug regimen.
UPDATED: Bristol-Myers makes Opdivo pitch for frontline lung cancer with open label PhIII study
Despite a head start, when Bristol-Myers Squibb and its pioneering checkpoint inhibitor Opdivo suffered a key lung cancer setback in 2016, they found themselves relegated to the backseat as Merck’s Keytruda seized the wheel on the road to immunotherapy stardom. Bristol-Myers has since suffered blow after blow in its quest to take a big slice of the lucrative market, peppered with some small successes. On Tuesday, the New Jersey drugmaker touted positive data from a Phase III open-label study in a bid to carve itself a piece of the frontline lung cancer market.
Takeda tees up $420M deal for celiac antidote, continuing R&D refocus
Sometime in the 1st century AD, a patient presented to Arataeus looking like a varicose ghost. He was “emaciated and atrophied, pale, feeble and incapable of performing any of his accustomed works,” the Greek physician wrote, with hollow temples and huge veins running all over his body.
A dysfunctional digestive system, Arataeus concluded – an imbalance he attributed to a “heat” deficiency in a system he and other Greeks regarded as functioning similarly to an oven – and coined a term: coeliac disease, after the Greek word for abdomen.
IMbrave150: Roche’s regulatory crew plans a global rollout of Tecentriq combo for liver cancer as PhIII scores a hit
Just weeks after Bristol-Myers Squibb defended its failed pivotal study pitting Opdivo against Nexavar in liver cancer, Roche says it’s beat the frontline challenge with a combination of their PD-L1 Tecentriq with Avastin. And now they’re rolling their regulatory teams in the US, Europe and China in search of a new approval — badly needed to boost a trailing franchise effort.
Given their breakthrough and Big Pharma status as well as the use of two approved drugs, FDA approval may well prove to be something of a formality. And the Chinese have been clear that they want new drugs for liver cancer, where lethal disease rates are particularly high.
Researchers at their big biotech sub, Genentech, say that the combo beat Bayer’s Nexavar on both progression-free survival as well as overall survival — the first advance in this field in more than a decade. We won’t get the breakdown in months of life gained, but it’s a big win for Roche, which has lagged far, far behind Keytruda and Opdivo, the dominant PD-1s that have captured the bulk of the checkpoint market so far.
Researchers recruited hepatocellular carcinoma — the most common form of liver cancer — patients for the IMbrave150 study who weren’t eligible for surgery ahead of any systemic treatment of the disease.
Roche has a fairly low bar to beat, with modest survival benefit for Nexavar, approved for this indication 12 years ago. But they also plan to offer a combo therapy that could have significantly less toxicity, offering patients a much easier treatment regimen.
Cowen’s Steven Scala recently sized up the importance of IMbrave150, noting:
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,800+ biopharma pros reading Endpoints daily — and it's free.
